2,2',4,6,6'-pentachlorobiphenyl, also known as PCB 153, is a highly chlorinated polychlorinated biphenyl (PCB) congener. It is a persistent organic pollutant (POP) and a known environmental contaminant. PCB 153 is often used as a marker for total PCB contamination in environmental samples. It is a non-flammable, colorless, viscous liquid with a melting point of 60-62 degrees Celsius. PCBs are synthesized through the reaction of chlorine with biphenyl in the presence of a catalyst, typically a Lewis acid. This congener is particularly persistent in the environment and accumulates in the food chain, especially in fatty tissues of animals. It is classified as a probable human carcinogen by the International Agency for Research on Cancer (IARC). PCB 153 has been linked to various adverse health effects in humans and animals, including endocrine disruption, immune system suppression, reproductive problems, developmental toxicity, and cancer. Its presence in the environment is a major concern, as it can bioaccumulate in organisms and pose a threat to human and ecosystem health. The persistence, bioaccumulation, and toxic effects of PCB 153 make it a primary target for environmental monitoring and remediation efforts.'
ID Source | ID |
---|---|
PubMed CID | 91662 |
SCHEMBL ID | 4452879 |
MeSH ID | M0375116 |
Synonym |
---|
1,1'-biphenyl, 2,2',4,6,6'-pentachloro- |
2,2',4,6,6'-pentachloro-1,1'-biphenyl |
pcb 104 |
2,2',4,6,6'-pentachlorobiphenyl |
2,4,6,2',6'-pentachlorobiphenyl |
1,3,5-trichloro-2-(2,6-dichlorophenyl)benzene |
56558-16-8 |
unii-z4yyf101n3 |
z4yyf101n3 , |
SCHEMBL4452879 |
MTCPZNVSDFCBBE-UHFFFAOYSA-N |
DTXSID0074184 , |
1,1'-biphenyl, 2,2',4,6,6'-pentachloro-; 2,2',4,6,6'-pentachloro-1,1'-biphenyl; 2,2',4,6,6'-pentachlorobiphenyl; 2,4,6,2',6'-pentachlorobiphenyl; pcb 104; 2,2',4,6,6'-pentacb |
pcb no. 104 |
Q27294999 |
CS-0453782 |
dtxcid4042090 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (80.00) | 29.6817 |
2010's | 2 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.63) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (10.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (90.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |